Immunohistochemical staining of MLH-1 of human FFPE tissue followed by incubation with HRP labeled secondary and development with DAB substrate.

MLH-1 [G168-15] Antibody (cGMP).

Name: MLH-1 [G168-15] Antibody (cGMP).
Brand: enQuire Bio
Price: 135 USD
Availability: InStock

$ 135.00 – $ 675.00

Please Select Product Options Below To View The Catalog Number.

SKU: QIVD150
Species: Human
Tested Applications: IHC [IVD]
Available Conjugates:
Isotype: Mouse IgG1

Product Number	Description	Price
QIVD150-0.1ml	Size: 0.1 ml, Format: Concentrate	$ 135.00
QIVD150-0.5ml	Size: 0.5 ml, Format: Concentrate	$ 405.00
QIVD150-1ml	Size: 1 ml, Format: Concentrate	$ 675.00
QIVD150-6ml	Size: 6 ml, Format: Predilute	$ 275.00

Shipping Information

In Stock

Flat Rate Shipping Anywhere in the US: $45

Datasheets and Documentation

Product Datasheet

Certificate of Analysis and Tags (Coming Soon)

SKU: QIVD150-0.1ml

MLH-1 General Information
Alternate Names

Molecular Weight
84.6 kDa
Chromosomal Location
p22.2 [chr: 3] [chr_start: 36993332] [chr_end: 37050918] [strand: 1]
Curated Database and Bioinformatic Data
Gene Symbol	MLH1
Entrez Gene ID	4292
RefSeq Protein Accession(s)	NP_000240; NP_001161089; NP_001161090; NP_001161091; XP_005265220; NP_001245200; XP_005265221; NP_001245203; NP_001245202
RefSeq mRNA Accession(s)	XM_017006450; NM_001354621; NM_001354627; NM_001354628; NM_001354615; NM_001354619; NM_001354624; NM_001354625; NM_001167618; NM_001258273; NM_001258274; NM_001354617; NM_001354620; NM_001354622; NM_001354629; NM_001258271; NM_001354616; NM_001354626; NM_001167617; NM_001354618; NM_000249; NM_001354623; NM_001354630; XM_005265161; NM_001167619
RefSeq Genomic Accession(s)	NG_007109; NC_000003
UniProt ID(s)	P40692
PharmGKB ID(s)	PA240
KEGG Gene ID(s)	hsa:4292
Associated Diseases (KEGG IDs)	Hereditary non-polyposis colorectal cancer 2 (HNPCC2) [MIM:609310]: An autosomal dominant disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. {ECO:0000269\|PubMed:10323887, ECO:0000269\|PubMed:10375096, ECO:0000269\|PubMed:10386556, ECO:0000269\|PubMed:10413423, ECO:0000269\|PubMed:10480359, ECO:0000269\|PubMed:10598809, ECO:0000269\|PubMed:10627141, ECO:0000269\|PubMed:10660333, ECO:0000269\|PubMed:10671064, ECO:0000269\|PubMed:10713887, ECO:0000269\|PubMed:10777691, ECO:0000269\|PubMed:10882759, ECO:0000269\|PubMed:11139242, ECO:0000269\|PubMed:11427529, ECO:0000269\|PubMed:11726306, ECO:0000269\|PubMed:11748856, ECO:0000269\|PubMed:11754112, ECO:0000269\|PubMed:11781295, ECO:0000269\|PubMed:11793442, ECO:0000269\|PubMed:11839723, ECO:0000269\|PubMed:11870161, ECO:0000269\|PubMed:12095971, ECO:0000269\|PubMed:12132870, ECO:0000269\|PubMed:12200596, ECO:0000269\|PubMed:12362047, ECO:0000269\|PubMed:12373605, ECO:0000269\|PubMed:12655562, ECO:0000269\|PubMed:12658575, ECO:0000269\|PubMed:14635101, ECO:0000269\|PubMed:14961575, ECO:0000269\|PubMed:15064764, ECO:0000269\|PubMed:15139004, ECO:0000269\|PubMed:15365995, ECO:0000269\|PubMed:15365996, ECO:0000269\|PubMed:16083711, ECO:0000269\|PubMed:16451135, ECO:0000269\|PubMed:17301300, ECO:0000269\|PubMed:17510385, ECO:0000269\|PubMed:18561205, ECO:0000269\|PubMed:20020535, ECO:0000269\|PubMed:21120944, ECO:0000269\|PubMed:22753075, ECO:0000269\|PubMed:7757073, ECO:0000269\|PubMed:8566964, ECO:0000269\|PubMed:8571956, ECO:0000269\|PubMed:8797773, ECO:0000269\|PubMed:8872463, ECO:0000269\|PubMed:8993976, ECO:0000269\|PubMed:9048925, ECO:0000269\|PubMed:9067757, ECO:0000269\|PubMed:9218993, ECO:0000269\|PubMed:9272156, ECO:0000269\|PubMed:9298827, ECO:0000269\|PubMed:9311737, ECO:0000269\|PubMed:9326924, ECO:0000269\|PubMed:9399661, ECO:0000269\|PubMed:9559627, ECO:0000269\|PubMed:9718327, ECO:0000269\|PubMed:9833759, ECO:0000269\|PubMed:9927034, ECO:0000269\|Ref.5}. The disease is caused by mutations affecting the gene represented in this entry.; Mismatch repair cancer syndrome (MMRCS) [MIM:276300]: An autosomal recessive, rare, childhood cancer predisposition syndrome encompassing a broad tumor spectrum. This includes hematological malignancies, central nervous system tumors, Lynch syndrome-associated malignancies such as colorectal tumors as well as multiple intestinal polyps, embryonic tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature reminiscent of neurofibromatosis type 1, are often found as first manifestation of the underlying cancer. Areas of skin hypopigmentation have also been reported in MMRCS patients. {ECO:0000269\|PubMed:11427529, ECO:0000269\|PubMed:17440981, ECO:0000269\|PubMed:7661930}. The disease is caused by mutations affecting the gene represented in this entry.; Muir-Torre syndrome (MRTES) [MIM:158320]: Rare autosomal dominant disorder characterized by sebaceous neoplasms and visceral malignancy. {ECO:0000269\|PubMed:8751876}. The disease is caused by mutations affecting the gene represented in this entry.; Defects in MLH1 may contribute to lobular carcinoma in situ (LCIS), a non-invasive neoplastic disease of the breast.; Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Disease susceptibility is associated with variations affecting the gene represented in this entry.; Some epigenetic changes can be transmitted unchanged through the germline (termed 'epigenetic inheritance'). Evidence that this mechanism occurs in humans is provided by the identification of individuals in whom 1 allele of the MLH1 gene is epigenetically silenced throughout the soma (implying a germline event). These individuals are affected by HNPCC but does not have identifiable mutations in MLH1, even though it is silenced, which demonstrates that an epimutation can phenocopy a genetic disease.; Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. {ECO:0000269\|PubMed:10598809, ECO:0000269\|PubMed:10882759, ECO:0000269\|PubMed:12132870, ECO:0000269\|PubMed:12655564, ECO:0000269\|PubMed:14504054, ECO:0000269\|PubMed:15184898, ECO:0000269\|PubMed:18033691, ECO:0000269\|PubMed:8872463, ECO:0000269\|PubMed:9032648, ECO:0000269\|PubMed:9087566, ECO:0000269\|PubMed:9611074}. Disease susceptibility is associated with variations affecting the gene represented in this entry.
General Description of MLH-1 .
The G168-15 antibody recognizes human and mouse MLH1 (80-85kDa). The repair of mismatch DNA is essential to maintaining the integrity of genetic information over time. An alteration of microsatellite repeats is the result of slippage owing to strand misalignment during DNA replication and is referred to as microsatellite instability (MSI). These defects in DNA repair pathways have been related to human carcinogenesis. The importance of mismatch repair genes became apparent with the identification of the genetic basis for hereditary nonpolyposis colon cancer (HNPC). MSH-2 is involved in the initial cognition of mismatch nucleotides during the replication mismatch repair process. It is thought that after MSH2 binds to a mismatched DNA duplex it is joined by a heterodimer of MLH1 and PMSH, which together help facilitate the later steps in mismatch repair.

Antibody (Suitable for clinical applications)

Sample Type: FFPE Patient Samples.

Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.

Application Notes

Specification	Recommendation
Recommended Dilution (Conc)	1:25-1:50
Pretreatment	EDTA Buffer pH8.0
Incubation Parameters	60 min at Room Temperature

Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.

Clonality: Monoclonal

Anti-MLH-1 Antibody Clone: G168-15

Host and Isotype: Mouse IgG1

Recommended Positive Control Sample: Tonsil, colon carcinoma

Cellular Localization of Antibody G168-15 Staining: Nuclear

Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN₃

Antibody Concentration: Lot specific. Plese contact tech support for data.

Immunogen: Full length recombinant MLH.

Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.

MLH-1 Information for Pathologists

Summary:

Mismatch repair gene. Mutations associated with Lynch syndrome (hereditary non-polyposis colon cancer) and some cases of sporadic colon cancer. Terminology Also called MutL homolog 1 colon cancer nonpolyposis type 2 (NCBI-Gene), hMLH1. Pathophysiology

Common Uses By Pathologists:

Use immunostaining for MLH1, MSH2, PMS2 and MSH6 to screen for Lynch syndrome. Biopsy samples may be as reliable as resections (Am J Surg Pathol 2011;35:447). Use of only PMS2 and MSH6 antibodies may be as effective as using all 4 antibodies (Am J Surg Pathol 2009;33:1639, Mod Pathol 2011;24:1004). Cases with normal staining due to somatic hypermethylation can occur (Am J Surg Pathol 2011;35:1902). Microscopic (histologic) images

Limitations and Warranty

This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.

There are no reviews yet.

Be the first to review “MLH-1 [G168-15] Antibody (cGMP).” Cancel reply

Share a Protocol (View Reviewed Protocols Below)

Protocol Title

Materials

Methods

Notes

Please type the code above.

Alert me when someone comments on my protocol.

MLH-1 [G168-15] Antibody (cGMP).

Antibody (Suitable for clinical applications)

MLH-1 Information for Pathologists

Summary:

Common Uses By Pathologists:

Limitations and Warranty

Be the first to review “MLH-1 [G168-15] Antibody (cGMP).” Cancel reply

Protocol Title

Materials

Methods

Notes

Related Products

MLH-1 [G168-15] Antibody (cGMP).